News | Ablation Systems | July 24, 2017

Medtronic Announces First Enrollments in STOP AF First Clinical Trial

U.S. trial will evaluate cryoablation therapy with Medtronic’s Arctic Front Advance Cryoballoon as first-line treatment for symptomatic paroxysmal atrial fibrillation

Medtronic Announces First Enrollments in STOP AF First Clinical Trial

July 24, 2017 — Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary vein isolation (PVI) with the Arctic Front Advance Cryoballoon in patients with symptomatic paroxysmal atrial fibrillation (AF) prior to treatment with anti-arrhythmic medications. The first patient in the trial was recently enrolled at The Ohio State University Wexner Medical Center by Jaret Tyler, M.D.

STOP AF First is a prospective, interventional, multicenter, randomized, controlled, clinical trial that will enroll up to 210 patients at up to 30 sites in the United States. Patients will be randomized to cryoballoon ablation (treatment arm) or anti-arrhythmic drug (AAD) therapy (control arm), and followed for 12 months. Oussama Wazni, M.D., co-director of Atrial Fibrillation Center at Cleveland Clinic, serves as the study's national principal investigator.

Cryoballoon ablation is used in a minimally invasive procedure to isolate the pulmonary veins, which are a source of erratic electrical signals that cause AF. The device uses cold energy (freezing) rather than heat (radiofrequency) to create scar tissue and interrupt irregular electrical pathways in the heart.

The 2016 European Society of Cardiology's (ESC) guidelines and the recent 2017 Heart Rhythm Society (HRS) Consensus Statement for the management of atrial fibrillation both acknowledge cryoablation therapy as an appropriate ablation energy for treating AF, and recognize PVI as an effective and preferred treatment option for select patients with AF.

In the United States, first-line treatment of symptomatic paroxysmal AF with the Arctic Front Advance Cryoablation System is investigational use only; the system is approved in the U.S. for the treatment of drug refractory, recurrent, symptomatic paroxysmal AF, and in Europe for the treatment of atrial fibrillation. More than 250,000 patients in more than 50 countries worldwide have been treated with the cryoballoon.

For more information: www.medtronic.com

Related Content

The Acutus Medical AcQBlate Force sensing ablation catheter.

The Acutus Medical AcQBlate Force sensing ablation catheter.

News | Ablation Systems | April 05, 2021
April 5, 2021 — Acutus Medical today announced initial U.S.
The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...